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proper selection of beam orientations. With intensity 
modulated radiotherapy (IMRT) highly conformal dose 
distribution can be achieved, but volumes irradiated by low 
doses can be larger than with 3D-CRT. Regarding the dose to 
OARs, with multicatheter BT the critical structures can be 
better spared than with 3D-CRT/IMRT except for the heart 
whose dose in BT is strongly dependent on the location of the 
PTV. With image guidance in EBRT the dose to OARs can be 
significantly reduced. At left sided lesion the dose to heart 
can be considerably decreased with deep inspiration breath-
hold technique. 
With special EBRT equipments such as Cyberknife or 
Tomotherapy which are equipped with image guidance 
smaller CTV-PTV margin can applied which reduces the dose 
to OARs while maintaining proper target coverage. Real-time 
tracking with Cyberknife can provide better target volume 
coverage and spare nearby critical organs, but the treatment 
time is too long.  
Proton beam irradiation, due to the more favourable dose 
characteristics of proton beam, can provide the less dose to 
organs at risk, but the availability of the technique is sparse.  
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During the past decade many investigations have been 
performed to investigate and minimize clinical uncertainties 
that could lead to significant deviations between the planned 
and the delivered doses in radiotherapy. Among the sources 
of uncertainties patient setup plays an important role in 
EBRT. Analogously, in brachytherapy the geometric 
uncertainties caused by movement or reconstruction 
uncertainties of the implant position in relation to the CTV 
and/or normal tissue can lead to systematic or random 
variations between prescribed and delivered dose. At the 
same time interfraction or intrafraction variations of the 
anatomy, e.g. caused by variations of position, shape and 
filling status of OARs, during the course of a treatment pose 
an additional challenge to all types of radiotherapy. 
Recent investigations of different types of uncertainties for a 
variety of treatment sites, including gynaecological, 
prostate, head and neck, or breast BT, have led to numerous 
reports on accuracy of image guided brachytherapy. These 
have triggered the development of the recommendations for 
reporting uncertainties in terms of their dosimetric impact 
(GEC-ESTRO / AAPM guidelines, Kirisits et al. 2014, Radiother 
Oncol 110). Following these guidelines for uncertainty 
analysis, individual BT workflows can be analysed in order to 
identify those components of the overall uncertainty budget 
which will have the largest impact on the total delivered 
treatment dose. Once identified, strategies for reducing 
these uncertainties can be taken into consideration, such as 
repetitive/near treatment imaging, advanced online dose 
verification tools, etc.  
In order to assess the clinical benefit of such uncertainty 
reduction measures, it is important to understand the 
interplay between different types of uncertainties and their 
combined effect on clinical outcome, in terms of TCP and 
NTCP. In the past, dose-response relationships have been 
derived from clinical data, which could not take into account 
the accuracy of the reported dose. For some treatment sites, 
e.g. for cervical cancer, uncertainty budgets and dose-
response relations have been described in the literature in 
sufficient detail that now allows us to simulate what impact 
specific clinical uncertainties would have on TCP/NTCP 
modelling. In addition to that, one can simulate how TCP or 
NTCP models would change, if systematic and random 
dosimetric uncertainties could be reduced.  
In this presentation a few such simulation examples will be 
shown to illustrate the clinical impact of uncertainties for 
source calibration, applicator reconstruction, interobserver 
variations and anatomical interfraction variations. Strategies 
for reducing clinical uncertainties will be discussed.  
Finally, we will come one step closer to answering the 
questions whether reducing our clinical uncertainties is 
possible and meaningful, and if so, which strategies would 
have the largest clinical impact. In the future dose 
prescription may be affected by technological improvements 
that lead to a reduction of dosimetric uncertainties and a 
subsequent widening of the therapeutic window. These 
developments would benefit from a common effort in the BT 
community to investigate dose-response relationships for 
various treatment sites, and to simultaneously report 
uncertainty budgets for the underlying workflows applied for 
image guided brachytherapy, in our current clinical practice.  
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The probability of local tumor control is limited by the 
amount of dose deliverable to the tumor, which is limited by 
the amount of radiation induced toxicity. There is a large, 
and currently unpredictable, interpatient variation in the 
amount of observed toxicity. Since the expected patient 
specific toxicity is not known, the prescribed dose is 
restricted such that, within the patient population, the 
number of patients with major or even fatale toxicity is 
limited. Due to the interpatient variation in toxicity the 
population based dose limits lead to undertreatment of 
patients with low normal tissue irradiation sensitivity. This 
issue could be addressed if, on a patient specific level, it 
would be possible to classify the patients according to 
expected toxicity prior to or early during the treatment 
course – which calls for predictive models of toxicity.  
Many clinical factors such as performance status, patient 
age, and other co-morbidity are associated with observed 
toxicity, and models based on such factors are today 
available (e.g. http://www.predictcancer.org/). The models 
can be a useful tool to optimize the treatment on the 
population level, but in order to be used on a patient specific 
level, input of more patient specific information is needed. 
During planning and delivery of radiotherapy a large number 
of patient images are acquired. The information content in 
the images is often reduced to a few figures (e.g. volume of 
tumor or measurement of patient positioning). The different 
types of images (CT/SPECT/PET/MR/CBCT) are available for 
free, and it is tempting to believe that these images could 
provide more patient specific information, if extracted in a 
proper way. Also as part of the response evaluation it is likely 
that imaging could be used to quantify the degree of toxicity. 
At the end of the day, the overall toxicity level can only be 
assessed by the patient, who should cope with the toxicity on 
a daily basis. However, in terms of biological tissue response 
to the radiation, patient (or oncologist) reported toxicity is 
likely to underestimate the “true” amount of toxicity since 
the toxicity effects might be overshadowed by treatment 
related gains e.g. re-ventilation of obstructed airways due to 
tumor regression in lung cancer patients, or because the 
toxicity is assumed to be related to co-morbidity. 
Disentanglement of such effects is desirable during creation 
of predictive models of toxicity; which might be feasible by 
evaluation of follow-up images.  
The most used imaging-based feature to predict toxicity is 
obviously measurement of dose to individual risk organs (e.g. 
dose to heart or lung). These values are routinely used 
clinically and typical not regarded as image-based features. 
More advanced imaging-based features such as homogeneity, 
texture, or time changes of signals/images has been proposed 
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and showed to be associated with toxicity. It is important to 
remember that such features, to some extent, might be 
confounded by more simple factors (e.g. tumor volume or 
volume of irradiated region). Nevertheless, image based 
features appears in a number of studies to add independent 
toxicity information; but it is likely that no single image-
based feature (or no single feature at all) will be able to 
make a perfect patient specific toxicity prediction for the 
entire population. In many studies the correlation between a 
specific image-based feature and observed toxicity is relative 
weak. However, if predictive toxicity models simply are able 
to identify a subset of patients who are likely to have modest 
toxicity that would be very beneficial, since this group of 
patients could then be offered a more aggressive treatment, 
which hopeful would result in improved local control. 
Predictive toxicity models should thus not only be evaluated 
on their overall prediction performance for the entire 
population, but also on their ability to identify a significant 
subgroup of patients who are candidates for intensified 
treatment.  
The current lecture will present examples of image-based 
features and point to their potential clinical impact; but will 
also focus on the potential use of patient specific toxicity 
models to select subgroups of patients as described above. 
Moreover comments on image quality will be made, since 
high images quality is the foundation for imaged-based 
features used in predictive models for toxicity. 
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In the field of toxicity modeling it is common practice to 
build statistical models starting from analysis of clinical data 
which are prospectively collected in the frame of 
observational trials. Modern prospective observational studies 
devoted to modelling of radioinduced toxicity are often 
accumulating a large amount of dosimetric and patient-
related information, this requires particular attention when 
normal tissue complication probability modelling is 
approached. A core issues is related to selection of features, 
which then influences overfitting, discrimination, 
personalization and generalizability.  
These risks are particularly high in clinical research datasets, 
which are often characterized by low cardinality - i.e. the 
number of cases is overall low - and are often strongly 
imbalanced in the endpoint categories – i.e. the number of 
positive cases (e.g. toxicity events or loss of disease control) 
is small, or even very small, with respect to the negative 
ones. This is obviously positive for patients, it is however a 
disadvantage for model building.  
In this context a possible methods using in-silico experiment 
approach for toxicity modelling will be discussed together 
with some applications.  
This method aimed at identifying the best predictors of a 
binary endpoint, with the purpose of detecting the leading 
robust variables and minimizing the noise due to the 
particular dataset, thus trying to avoid both under- and over-
fitting. It followed, with adjustments, a procedure firstly 
introduced by El Naqa [IJROBP2006]: the treatment response 
curve was approximated by the logistic function, while the 
bootstrap resamplings were performed to explore the 
recurrence of the selected variables in order to check their 
stability. A further bootstrap resampling was introduced for 
the evaluation of the odds ratios of the selected variables.  
The in-silico experiment was implemented using the KNIME 
software (KNIME GmbH, Germany) and consisted in the 
following processing steps:  
1) 1000 bootstrap samplings of the original dataset are 
created, as suggested by El Naqa [IJROBP2006];  
2) backward feature selection based on minimization of 
residuals is performed on each bootstrap sample;  
3) the rate of occurrences and the placement of each 
variable (selected by the backward feature selection) in the 
1000 bootstrapped datasets are used to classify the most 
robust predictors. A synthetic index, called normalized area, 
is defined for ranking each predictor: it corresponds to the 
area under the histogram representing the number of 
occurrences of each variable (x-axis) at a given importance 
level in each re-sampled dataset;  
4) a basket analysis of the 1000 sets of predictors is used to 
identify the predictors that appears together with higher 
probability;  
5) the best set of predictors is chosen, with its maximum size 
determined by the rule of thumb “one tenth of the number 
of toxicity events”; 
6) the distribution of odds ratios are determined through 
1000 bootstrap re-samplings of the original dataset including 
the set of predictors selected in the previous step;  
7) a logistic model with the best set of predictors and the 
median odds ratios, calculated from the distributions 
obtained in the previous step, is defined. 
In this approach, logistic regression is enhanced with 
upstream and downstream data processing to find stable 
predictors.  
The method was tested with satisfactory results on different 
datasets aimed at modelling radio-induced toxicity after 
high-dose prostate cancer radiotherapy. 
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Intensity modulated radiotherapy and volumetric modulated 
radiotherapy (VMAT) involves multiple manual steps, which 
might influence the plan quality and consistency, for example 
planning objectives and constraints need to be manually 
adapted to the patients individual anatomy, tumor location, 
size and shape [1]. Additional help structures are frequently 
defined on an individual basis to further optimize the 
treatment plan, resulting in an iterative process. This manual 
method of optimization is time consuming and the plan 
quality is strongly dependent on planner experience. This is 
especially true for complex cases such as head and neck (HN) 
carcinoma and stereotactic treatment. 
In order to improve the overall plan quality and consistency, 
and to decrease the time required for planning, automated 
planning algorithms have been developed [2,3]. In this pilot 
study, we compared two commercially available automatic 
planning systems for HN cancer patients. A VMAT model was 
created with a knowledge based treatment system, Auto-
Planning V9.10 (Pinnacle, Philips Radiation Oncology Systems, 
Fitchburg, WI) [4] and for a model based optimization 
system, RapidPlan V13.6 (Eclipse, Varian Medical System, 
Palo Alto, CA) [2]. These two models were used to optimize 
ten HN plans. Since the aim was to achieve plans of 
comparable quality to the manually optimized plans in a 
shorter time, only a single cycle of plan optimization was 
done for both automated treatment planning systems (TPS). 
Auto-Planning was additionally used to evaluate the 
treatment of lung and brain metastases stereotactic 
treatments.  
The results from the planning comparison for HN cancer 
patients showed a better target coverage with AutoPlanning 
in comparison to Rapidplan and manually optimized plans (p 
< 0.05). RapidPlan achieved better dose conformity in 
comparison to AutoPlanning (p < 0.05). No significant 
differences were observed for the OARs, except for the 
swallowing muscles where RapidPlan and the manually 
optimized plans were better than AutoPlanning and for the 
mandibular bones were AutoPlanning performed better than 
the two other systems. The working time needed to generate 
